BioLineRx

BioLineRx Announces $6 Million Registered Direct Offering

Retrieved on: 
Monday, April 1, 2024
Patient, Sale, Multiple myeloma, Attention, American depositary receipt, ADS, Security (finance), Prospectus, Pancreatic cancer, BioLineRx, Equity capital markets, File, TEL

Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx.

Key Points: 
  • Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx.
  • The offering is expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants), before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be $6.0 million.
  • The offering is being made by the Company pursuant to its shelf registration statement on Form F-3 (File No.

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Retrieved on: 
Wednesday, March 20, 2024
Conference, Conference call, TEL, EDT, BioLineRx

TEL AVIV, Israel, March 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.

Key Points: 
  • The Company will host a conference call at 08:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
  • To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally.
  • A live webcast and a replay of the call can be accessed through the event page on the Company's website.
  • A dial-in replay of the call will be available until March 28, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
Wednesday, March 6, 2024
Radiation, Doctor of Philosophy, Immunotherapy, News, FOLFIRINOX, Growth, CADL, PR, CXCR4, Lead, PRS, Multiple myeloma, Poster, Pancreatic cancer, Gemcitabine, Fast Track, Liver, Incidence, Cancer, City, HSC, Chung, TME, Overalls, FACP, Therapy, Sickle cell disease, Columbia University, MAPK, Immune system, SNF, G-CSF, Woman, AIO, SCD, AACR, PD-1, Conference, TILS, Tumor microenvironment, BioLineRx, Clinical trial, Survival, Oncology, Filgrastim, Collection, American Cancer Society, Caregiver, USD, SWI, MD, Blood, FDA, TSX, Biotechnology, Pancreatic Cancer Action Network, Stem cell, RAS, Valaciclovir, PDAC, Patient, Natalizumab, ONC, PEI, Pharmaceutical industry

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Retrieved on: 
Wednesday, February 28, 2024
Liver, Collection, Immunotherapy, FDA, TEL, Pancreatic cancer, HSC, SCD, Stem cell, AACR, PD-1, Conference, CXCR4, Lead, PDAC, PRS, BioLineRx, Patient, Sickle cell disease, Multiple myeloma, Columbia University, Filgrastim, Natalizumab, Cancer, Gemcitabine, Pharmaceutical industry

TEL AVIV, Israel, Feb. 28, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC). The investigator-initiated trial is being conducted in collaboration with Columbia University and is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies.

Key Points: 
  • The investigator-initiated trial is being conducted in collaboration with Columbia University and is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies.
  • "We are encouraged by our early pilot data and look forward to continuing to advance the expanded, randomized Phase 2 CheMo4METPANC trial for patients living with this cancer."
  • The findings were previously presented during an oral presentation at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston, Massachusetts, September 28, 2023.
  • Motixafortide is also being evaluated in a Phase 1 clinical trial evaluating motixafortide as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD).

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Friday, February 16, 2024
G-CSF, PD, CD34, TEL, HSC, Stem cell, Safety, Society, Pharmacokinetics, GENESIS, BioLineRx, Patient, Multiple myeloma, Transplant, Filgrastim, Risk, Dentistry

Phase 1 study results demonstrated an extended PD effect with complete receptor occupancy by motixafortide starting at a concentration of 3nM.

Key Points: 
  • Phase 1 study results demonstrated an extended PD effect with complete receptor occupancy by motixafortide starting at a concentration of 3nM.
  • In the GENESIS trial, post-hoc subgroup analyses based on baseline characteristics and risk factors for impaired HSC mobilization demonstrated a consistent benefit of motixafortide + G-CSF over placebo + G-CSF mobilization for all patients.
  • Poster Presentations at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the ASTCT and the CIBMTR.
  • Title: Motixafortide Enables Consistent, Robust Hematopoietic Stem Cell Collection (HSC) across Populations with Increased Impaired HSC Mobilization: A Sub-Group Analysis of the Genesis Study
    Presenter: Zachary D. Crees, MD, Washington University School of Medicine in St. Louis

PRISM MarketView Honors National Biotechnology Month with a Spotlight on Emerging Biotech Innovators

Retrieved on: 
Tuesday, January 9, 2024
President Clinton, Bristol Myers Squibb, Eye, PRISM, BioLineRx, Regenerative medicine, Duchenne muscular dystrophy, Health, Biotechnology, MUSCULAR, Genetics, Cancer, Genomics, Disease, Sickle cell disease, Natalizumab

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- In celebration of National Biotechnology Month, PRISM MarketView acknowledges the significant advancements in biotechnology since its establishment by President Clinton in 2000.

Key Points: 
  • NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- In celebration of National Biotechnology Month, PRISM MarketView acknowledges the significant advancements in biotechnology since its establishment by President Clinton in 2000.
  • Aligning with this spirit of innovation and progress, PRISM MarketView is spotlighting the PRISM Emerging Biotech Index .
  • In honor of National Biotechnology Month, PRISM MarketView is excited to spotlight three trailblazing companies within our biotech index.
  • During National Biotechnology Month and throughout the year, PRISM MarketView’s Biotech index keeps a close eye on small and micro-cap stocks that are contributing to innovation in this critical sector.

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Retrieved on: 
Monday, November 20, 2023
NDA, Pancreatic cancer, Safety, Research, NCCN, Sickle cell disease, ASH, Liver, Clinical trial, Patient, PRS, Natalizumab, FDA, Marketing, PDAC, G&A, Conference, Partnership, EST, Biomarker, Columbia University, Society, TEL, BioLineRx, GENESIS, Poster, TASE, AACR, Pharmaceutical industry, Rare-earth element, Cryptocurrency

- Management to host conference call today, November 20, at 10:00 a.m. EST -

Key Points: 
  • - Management to host conference call today, November 20, at 10:00 a.m. EST -
    TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates.
  • "In addition, the company also closed its motixafortide licensing agreement covering the important Asia market.
  • The highly encouraging data triggered a change in the protocol, from a small, single-arm study to a much larger randomized study.
  • A dial-in replay of the call will be available until November 22, 2023; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, FDA, MSQ, BioLineRx, PD-1, Drug development, Agility, Partnership, Pancreatic cancer, Patient, Sales, Pharmaceutical industry

Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.

Key Points: 
  • Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.
  • "Given GloriaBio's expertise and track record in the development and commercialization of cancer immunotherapies in China, we believe GloriaBio is well suited to further develop motixafortide in Asia.
  • The MSQ team showed remarkable agility and a deep understanding of mutual benefits to both parties right from our initial discussions.
  • As part of this momentous partnership, we eagerly anticipate the positive developments ahead, promising an even brighter future for global patients."

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, FDA, MSQ, BioLineRx, PD-1, Drug development, Agility, Partnership, Pancreatic cancer, Patient, Sales, Pharmaceutical industry

Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.

Key Points: 
  • Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.
  • "Given GloriaBio's expertise and track record in the development and commercialization of cancer immunotherapies in China, we believe GloriaBio is well suited to further develop motixafortide in Asia.
  • The MSQ team showed remarkable agility and a deep understanding of mutual benefits to both parties right from our initial discussions.
  • As part of this momentous partnership, we eagerly anticipate the positive developments ahead, promising an even brighter future for global patients."

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

Retrieved on: 
Thursday, October 12, 2023
Partnership, Food, TEL, AACR, Multiple myeloma, ADS, ASCT, Columbia University, SCM, FDA, American Association for Cancer Research, Pancreatic cancer, CXCR4, Rare, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TASE, American depositary receipt, BioLineRx, Conference, PD-1, Patient, Sales, Pharmaceutical industry

TEL AVIV, Israel, Oct. 12, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia. Motixafortide is a novel, high-affinity CXCR4 inhibitor that received approval for its first indication in September 2023 by the U.S. Food and Drug Administration (FDA) for stem cell mobilization (SCM) in autologous stem cell transplantation (ASCT) in patients with multiple myeloma. Motixafortide is also being studied for other potential uses in oncologic and hematologic diseases.

Key Points: 
  • Motixafortide is also being studied for other potential uses in oncologic and hematologic diseases.
  • In addition, the transaction included an equity investment of $14.6 million in BioLineRx through the purchase of newly issued American Depositary Shares (ADSs) at a price of $2.136 per ADS in a private placement.
  • Along with the investment, the purchaser received the right to appoint one representative to the BioLineRx Board of Directors.
  • Under the terms of the license agreement, GloriaBio will be responsible for development and commercialization of motixafortide in Asia initially in SCM.